Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Stage A Prostate Cancer Clear all
Recruiting Phase 2 Interventional

PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

NCT07550517
View directory record Official record
Conditions
High-Risk Localized Prostate Cancer
Interventions
EBRT + 6 mo ADT + 177Lu-PSMA-617, EBRT + 24 mo ADT
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 4:53 AM EDT
Not listed Phase 1 Interventional

Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas

NCT05415098
View directory record Official record
Conditions
Nasopharyngeal Carcinoma, Castrate Resistant Prostate Cancer, Gastric Cancer, Ovarian Clear Cell Carcinoma, Mesothelioma, Sarcoma, Non Hodgkin Lymphoma, B Cell Lymphoma, Epithelioid Sarcoma
Interventions
APG-5918
Drug
Lead sponsor
Ascentage Pharma Group Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Springdale, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Results available

A Trial of CTT1403 for Metastatic Castration Resistant Prostate Cancer

NCT03822871
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTT1403, CTT1057, 68Ga-PSMA-11
Drug
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

NCT02059213
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ibrance, Bicalutamide, Zoladex, Lupron Depot
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
8
States / cities
Duarte, California • Chicago, Illinois • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

NCT01543776
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Stage IV Prostate Cancer
Interventions
abiraterone acetate
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Evanston, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Randomized Study of Testosterone Replacement in Patients With Low Risk Hormone Refractory Prostate Cancer

NCT01187485
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androderm® 2.5mg, Androderm® 5.0mg, Androderm® 7.5mg
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

NCT02740985
View directory record Official record
Conditions
Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)
Interventions
AZD4635, Durvalumab, Abiraterone Acetate, Enzalutamide, Oleclumab, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
17
States / cities
Fayetteville, Arkansas • Fresno, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Preoperative Radiation Therapy for High Risk Prostate Cancer

NCT01041326
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Radical Prostatectomy
Radiation · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection

NCT04838626
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer
Interventions
[18F]CTT1057
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 25, 2026, 4:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer

NCT00536991
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
Calcitriol, Ketoconazole, Laboratory Biomarker Analysis, Pharmacological Study, Therapeutic Hydrocortisone
Dietary Supplement · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 25, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

NCT05766371
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Carcinoma
Interventions
Pembrolizumab, 177Lu-PSMA-617
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer

NCT03739684
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
18F-DCFPyL, PET/CT Imaging
Drug · Diagnostic Test
Lead sponsor
Progenics Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients

NCT00466440
View directory record Official record
Conditions
Prostate Cancer
Interventions
enzastaurin, placebo, docetaxel, prednisone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
22
States / cities
Fullerton, California • Los Angeles, California • Northridge, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2020 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel

NCT00096499
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
ispinesib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

AGS-1C4D4 in Patients With Advanced Hormone Refractory Prostate Cancer

NCT00519233
View directory record Official record
Conditions
Prostate Cancer
Interventions
AGS-1C4D4
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Sep 25, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab

NCT06782555
View directory record Official record
Conditions
Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Interventions
Evofosfamide, Zalifrelimab, Balstilimab
Drug
Lead sponsor
ImmunoGenesis
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Enzalutamide in Patients With High-risk Prostate Cancer

NCT01927627
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
enzalutamide
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional

ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer

NCT00477529
View directory record Official record
Conditions
Hormone Refractory Prostate Cancer
Interventions
ABI-008
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy

NCT00096551
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM), Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM), Recombinant Fowlpox-GM-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 25, 2026, 4:53 AM EDT
Not listed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer

NCT00003633
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, mitoxantrone hydrochloride, prednisone
Drug
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer

NCT01717053
View directory record Official record
Conditions
Prostate Cancer
Interventions
Abiraterone acetate, Androgen deprivation, Radiation Therapy, Prednisone
Drug · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
3
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT01848067
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Alisertib, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 3, 2025 · Synced Sep 25, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

Two Doses of Conjugated Estrogen (Premarin) in Patients With Androgen-Independent Prostate Cancer

NCT00134654
View directory record Official record
Conditions
Prostate Cancer
Interventions
Premarin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2011 · Synced Sep 25, 2026, 4:53 AM EDT